This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (200)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in JAMA  Topic Collections  • Cardiovascular System  • Randomized Controlled Trial  • Cardiovascular Disease/ Myocardial Infarction  • Alert me on articles by topic  Social Bookmarking   What's this?

A Randomized Controlled Trial

Gregg W. Stone, MD; Stephen G. Ellis, MD; Louis Cannon, MD; J. Tift Mann, MD; Joel D. Greenberg, MD; Douglas Spriggs, MD; Charles D. O'Shaughnessy, MD; Samuel DeMaio, MD; Patrick Hall, MD; Jeffrey J. Popma, MD; Joerg Koglin, MD; Mary E. Russell, MD; for the TAXUS V Investigators

JAMA. 2005;294:1215-1223.

Context  Compared with bare metal stents, drug-eluting stents reduce restenosis in noncomplex lesions. The utility of drug-eluting stents has not been evaluated in more difficult stenoses.

Objective  To investigate the safety and efficacy of the polymer-based, slow-release paclitaxel-eluting stent in a patient population with more complex lesions than previously studied.

Design, Setting, and Patients  Prospective, placebo-controlled, double-blind, multicenter randomized trial conducted from February 2003 to March 2004 at 66 academic and community-based institutions with 1156 patients who underwent stent implantation in a single coronary artery stenosis (vessel diameter, 2.25-4.0 mm; lesion length, 10-46 mm), including 664 patients (57.4%) with complex or previously unstudied lesions (requiring 2.25-mm, 4.0-mm, and/or multiple stents) and 9-month clinical and angiographic follow-up.

Interventions  Patients were randomly assigned to receive 1 or more bare metal stents (n = 579) or identical-appearing paclitaxel-eluting stents (n = 577).

Main Outcome Measure  Ischemia-driven target vessel revascularization at 9 months.

Results  Baseline characteristics were well matched. Diabetes was present in 31% of patients. The mean (SD) reference vessel diameter was 2.69 (0.57) mm, the reference lesion length was 17.2 (9.2) mm, and 78% of lesions were type B₂/C. A mean (SD) of 1.38 (0.58) stents (total mean [SD] length, 28.4 [13.1] mm) were implanted per lesion; 33% of lesions required multiple stents. Stents that were 2.25 mm and 4.0 mm in diameter were used in 18% and 17% of lesions, respectively. Compared with bare metal stents, paclitaxel-eluting stents reduced the 9-month rate of target lesion revascularization from 15.7% to 8.6% (P<.001) and target vessel revascularization from 17.3% to 12.1% (P = .02). Similar rates were observed for cardiac death or myocardial infarction (5.5% for bare metal stent group vs 5.7% for paclitaxel-eluting stent group) and stent thrombosis (0.7% in both groups). Angiographic restenosis was reduced from 33.9% to 18.9% in the entire study cohort (P<.001), including among patients receiving 2.25-mm stents (49.4% vs 31.2%; P = .01), 4.0-mm stents (14.4% vs 3.5%; P = .02), and multiple stents (57.8% vs 27.2%; P<.001).

Conclusion  Compared with a bare metal stent, implantation of the paclitaxel-eluting stent in a patient population with complex lesions effectively reduces clinical and angiographic restenosis.

Author Affiliations: Department of Cardiology, Columbia University Medical Center and Cardiovascular Research Foundation, New York, NY (Dr Stone); Department of Cardiology, Cleveland Clinic Foundation, Cleveland, Ohio (Dr Ellis); Department of Cardiology, Northern Michigan Hospitals, Petoskey (Dr Cannon); WakeMed, Raleigh, NC (Dr Mann); Department of Cardiology, Florida Heart Institute, Orlando (Dr Greenberg); Department of Cardiology, Morton Plant Hospital, Clearwater, Fla (Dr Spriggs); Department of Cardiology, Elyria Memorial Hospital, Elyria, Ohio (Dr O'Shaughnessy); Department of Cardiology, South Austin Hospital, Austin, Tex (Dr DeMaio); Department of Cardiology, South Carolina Heart Center, Columbia (Dr Hall); Department of Cardiology, Brigham and Women’s Hospital, Boston, Mass (Dr Popma); and Boston Scientific Corp, Natick, Mass (Drs Koglin and Russell).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

Paclitaxel-Eluting Stents in Complex Lesions
Antonio Colombo and John Cosgrave
JAMA. 2005;294(10):1268-1270.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Volumetric Intravascular Ultrasound Analysis of Paclitaxel-Eluting and Bare Metal Stents in Acute Myocardial Infarction: The Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction Intravascular Ultrasound Substudy
Maehara et al.
Circulation 2009;120:1875-1882.
ABSTRACT | FULL TEXT  

Dual antiplatelet therapy for more than 12 months after percutaneous coronary intervention: insights from the Guthrie PCI Registry
Harjai et al.
Heart 2009;95:1579-1586.
ABSTRACT | FULL TEXT  

Evaluation of Coronary Stents With 64-MDCT: In Vitro Comparison of Scanners From Four Vendors
Wolf et al.
Am. J. Roentgenol. 2009;193:787-794.
ABSTRACT | FULL TEXT  

Drug-Eluting Balloon: The Comeback Kid?
Waksman and Pakala
Circ Cardiovasc Interv 2009;2:352-358.
FULL TEXT  

Changing Volumes, Risk Profiles, and Outcomes of Coronary Artery Bypass Grafting and Percutaneous Coronary Interventions.
Aldea et al.
Ann. Thorac. Surg. 2009;87:1828-1838.
ABSTRACT | FULL TEXT  

Late Clinical Events After Drug-Eluting Stents: The Interplay Between Stent-Related and Natural History-Driven Events
Leon et al.
J Am Coll Cardiol Intv 2009;2:504-512.
ABSTRACT | FULL TEXT  

Long-Term Paclitaxel-Eluting Stent Outcomes in Elderly Patients
Forman et al.
Circ Cardiovasc Interv 2009;2:178-187.
ABSTRACT | FULL TEXT  

Paclitaxel- Versus Sirolimus-Eluting Stents for Unprotected Left Main Coronary Artery Disease
Mehilli et al.
J Am Coll Cardiol 2009;53:1760-1768.
ABSTRACT | FULL TEXT  

Comparison of Drug-Eluting Stents and Coronary Artery Bypass Surgery for the Treatment of Multivessel Coronary Disease: Three-Year Follow-Up Results From a Single Institution
Li et al.
Circulation 2009;119:2040-2050.
ABSTRACT | FULL TEXT  

Durability of Antirestenotic Efficacy in Drug-Eluting Stents With and Without Permanent Polymer
Byrne et al.
J Am Coll Cardiol Intv 2009;2:291-299.
ABSTRACT | FULL TEXT  

Endothelium-Dependent Vasomotor Dysfunction in Pig Coronary Arteries With Paclitaxel-Eluting Stents Is Associated With Inflammation and Oxidative Stress
Pendyala et al.
J Am Coll Cardiol Intv 2009;2:253-262.
ABSTRACT | FULL TEXT  

2-Year Clinical Outcomes After Implantation of Sirolimus-Eluting, Paclitaxel-Eluting, and Bare-Metal Coronary Stents Results From the WDHR (Western Denmark Heart Registry).
Kaltoft et al.
J Am Coll Cardiol 2009;53:658-664.
ABSTRACT | FULL TEXT  

Effect of Length and Diameter of Drug-Eluting Stents Versus Bare-Metal Stents on Late Outcomes
Circ Cardiovasc Interv 2009;2:35-42.
 

Stent Parameters Predict Major Adverse Clinical Events and the Response to Platelet Glycoprotein IIb/IIIa Blockade: Findings of the ESPRIT Trial
Tcheng et al.
Circ Cardiovasc Interv 2009;2:43-51.
ABSTRACT | FULL TEXT  

Should dual antiplatelet therapy after drug-eluting stents be continued for more than 1 year?: Dual Antiplatelet Therapy After Drug-Eluting Stents Should Not Be Continued for More Than 1 Year and Preferably Indefinitely
Colombo and Gerber
Circ Cardiovasc Interv 2008;1:226-232.
FULL TEXT  

Reduced Risk of Restenosis in Small Vessels and Reduced Risk of Myocardial Infarction in Long Lesions With the New Thin-Strut TAXUS Liberte Stent: 1-Year Results From the TAXUS ATLAS Program
Turco et al.
J Am Coll Cardiol Intv 2008;1:699-709.
ABSTRACT | FULL TEXT  

A Randomized, Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of Zotarolimus- Versus Paclitaxel-Eluting Stents in De Novo Occlusive Lesions in Coronary Arteries: The ZoMaxx I Trial
Chevalier et al.
J Am Coll Cardiol Intv 2008;1:524-532.
ABSTRACT | FULL TEXT  

Impact of In-Stent Minimal Lumen Area at 9 Months Poststent Implantation on 3-Year Target Lesion Revascularization-Free Survival: A Serial Intravascular Ultrasound Analysis From the TAXUS IV, V, and VI Trials
Doi et al.
Circ Cardiovasc Interv 2008;1:111-118.
ABSTRACT | FULL TEXT  

Drug-Eluting Stents Versus Bare-Metal Stents for Off-Label Indications: A Propensity Score-Matched Outcome Study
Austin et al.
Circ Cardiovasc Interv 2008;1:45-52.
ABSTRACT | FULL TEXT  

Coronary Artery Stents: Part I. Evolution of Percutaneous Coronary Intervention
Newsome et al.
Anesth. Analg. 2008;107:552-569.
ABSTRACT | FULL TEXT  

Clinical efficacy of drug-eluting stents in diabetic patients: a meta-analysis.
Mahmud et al.
J Am Coll Cardiol 2008;51:2385-2395.
ABSTRACT | FULL TEXT  

Long-Term Outcome in Patients Treated With Sirolimus-Eluting Stents in Complex Coronary Artery Lesions: 3-Year Results of the SCANDSTENT (Stenting Coronary Arteries in Non-Stress/Benestent Disease) Trial
Kelbaek et al.
J Am Coll Cardiol 2008;51:2011-2016.
ABSTRACT | FULL TEXT  

Drug-Eluting Stents: Life Insurance With a Better Death Benefit
Anderson
J Am Coll Cardiol 2008;51:2025-2027.
FULL TEXT  

Comparison of an Everolimus-Eluting Stent and a Paclitaxel-Eluting Stent in Patients With Coronary Artery Disease: A Randomized Trial
Stone et al.
JAMA 2008;299:1903-1913.
ABSTRACT | FULL TEXT  

A novel bioresorbable polymer paclitaxel-eluting stent for the treatment of single and multivessel coronary disease: primary results of the COSTAR (Cobalt Chromium Stent With Antiproliferative for Restenosis) II study.
Krucoff et al.
J Am Coll Cardiol 2008;51:1543-1552.
ABSTRACT | FULL TEXT  

Comparison of Coronary Artery Stenting Outcomes in the Eras Before and After the Introduction of Drug-Eluting Stents
Hannan et al.
Circulation 2008;117:2071-2078.
ABSTRACT | FULL TEXT  

Drug-Eluting Versus Bare-Metal Stents in the Treatment of Patients With ST-Segment Elevation Myocardial Infarction
Hannan et al.
J Am Coll Cardiol Intv 2008;1:129-135.
ABSTRACT | FULL TEXT  

Direct Stenting With the TAXUS Liberte Drug-Eluting Stent: Results From the TAXUS ATLAS DIRECT STENT Study
Ormiston et al.
J Am Coll Cardiol Intv 2008;1:150-160.
ABSTRACT | FULL TEXT  

Chronic Arterial Responses to Overlapping Paclitaxel-Eluting Stents: Insights From Serial Intravascular Ultrasound Analyses in the TAXUS-V and -VI Trials
Aoki et al.
J Am Coll Cardiol Intv 2008;1:161-167.
ABSTRACT | FULL TEXT  

Two-year clinical outcome after implantation of sirolimus-eluting and paclitaxel-eluting stents in diabetic patients
Billinger et al.
Eur Heart J 2008;29:718-725.
ABSTRACT | FULL TEXT  

The Problem With Composite End Points in Cardiovascular Studies The Story of Major Adverse Cardiac Events and Percutaneous Coronary Intervention.
Kip et al.
J Am Coll Cardiol 2008;51:701-707.
ABSTRACT | FULL TEXT  

Paclitaxel-Eluting Coronary Stents in Patients With Diabetes Mellitus Pooled Analysis From 5 Randomized Trials.
Kirtane et al.
J Am Coll Cardiol 2008;51:708-715.
ABSTRACT | FULL TEXT  

Balancing Efficacy and Safety of Drug-Eluting Stents in Patients Undergoing Percutaneous Coronary Intervention
Jeremias and Kirtane
ANN INTERN MED 2008;148:234-238.
ABSTRACT | FULL TEXT  

Drug-eluting stents: do the risks really outweigh the benefits?
Austin et al.
Heart 2008;94:127-128.
FULL TEXT  

Coronary artery aneurysms after drug-eluting stent implantation.
Aoki et al.
J Am Coll Cardiol Intv 2008;1:14-21.
ABSTRACT | FULL TEXT  

Drug-Eluting Stents vs. Coronary-Artery Bypass Grafting in Multivessel Coronary Disease
Hannan et al.
NEJM 2008;358:331-341.
ABSTRACT | FULL TEXT  

A Comparison of Bare-Metal and Drug-Eluting Stents for Off-Label Indications
Marroquin et al.
NEJM 2008;358:342-352.
ABSTRACT | FULL TEXT  

2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention
American College of Cardiology/American Heart Asso et al.
J Am Coll Cardiol 2008;51:172-209.
FULL TEXT  

2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to Review New Evidence and Update the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention, Writing on Behalf of the 2005 Writing Committee
King et al.
Circulation 2008;117:261-295.
FULL TEXT  

Angiographic surrogate end points in drug-eluting stent trials: a systematic evaluation based on individual patient data from 11 randomized, controlled trials.
Pocock et al.
J Am Coll Cardiol 2008;51:23-32.
ABSTRACT | FULL TEXT  

Myocardial Revascularization with Percutaneous Devices
Wilson and Willerson
Card Surg Adult 2008;3:573-598.
FULL TEXT  

Unrestricted Use of Drug-Eluting Stents Compared With Bare-Metal Stents in Routine Clinical Practice: Findings From the National Heart, Lung, and Blood Institute Dynamic Registry
Abbott et al.
J Am Coll Cardiol 2007;50:2029-2036.
ABSTRACT | FULL TEXT  

Meta-analysis of randomized trials on drug-eluting stents vs. bare-metal stents in patients with acute myocardial infarction
Kastrati et al.
Eur Heart J 2007;28:2706-2713.
ABSTRACT | FULL TEXT  

Randomized trial of rapamycin- and paclitaxel-eluting stents with identical biodegradable polymeric coating and design
Wessely et al.
Eur Heart J 2007;28:2720-2725.
ABSTRACT | FULL TEXT  

Comparative Clinical Outcomes of Paclitaxel- and Sirolimus-Eluting Stents: Results From a Large Prospective Multicenter Registry STENT Group
Simonton et al.
J Am Coll Cardiol 2007;50:1214-1222.
ABSTRACT | FULL TEXT  

Impact of Vessel Size on Outcome After Implantation of Sirolimus-Eluting and Paclitaxel-Eluting Stents: A Subgroup Analysis of the SIRTAX Trial
Togni et al.
J Am Coll Cardiol 2007;50:1123-1131.
ABSTRACT | FULL TEXT  

Drug-Eluting Stent Update 2007: Part III: Technique and Unapproved/Unsettled Indications (Left Main, Bifurcations, Chronic Total Occlusions, Small Vessels and Long Lesions, Saphenous Vein Grafts, Acute Myocardial Infarctions, and Multivessel Disease)
Colombo and Chieffo
Circulation 2007;116:1424-1432.
FULL TEXT  

Targeted stent use in clinical practice based on evidence from the Basel Stent Cost Effectiveness Trial (BASKET)
Agostoni et al.
Eur Heart J 2007;28:1912-1913.
FULL TEXT  

Stent Thrombosis, Myocardial Infarction, and Death After Drug-Eluting and Bare-Metal Stent Coronary Interventions
Jensen et al.
J Am Coll Cardiol 2007;50:463-470.
ABSTRACT | FULL TEXT  

Drug-Eluting Stent Update 2007: Part I: A Survey of Current and Future Generation Drug-Eluting Stents: Meaningful Advances or More of the Same?
Daemen and Serruys
Circulation 2007;116:316-328.
FULL TEXT  

Clinical impact of in-stent late loss after drug-eluting coronary stent implantation
Moreno et al.
Eur Heart J 2007;28:1583-1591.
ABSTRACT | FULL TEXT  

Effect of the polymer-based, paclitaxel-eluting TAXUS Express stent on vascular tissue responses: a volumetric intravascular ultrasound integrated analysis from the TAXUS IV, V, and VI trials
Weissman et al.
Eur Heart J 2007;28:1574-1582.
ABSTRACT | FULL TEXT  

Long-Term Safety and Efficacy of Drug-Eluting Stents: Two-Year Results of the REAL (REgistro AngiopLastiche dell'Emilia Romagna) Multicenter Registry
Marzocchi et al.
Circulation 2007;115:3181-3188.
ABSTRACT | FULL TEXT  

Offsetting Impact of Thrombosis and Restenosis on the Occurrence of Death and Myocardial Infarction After Paclitaxel-Eluting and Bare Metal Stent Implantation
Stone et al.
Circulation 2007;115:2842-2847.
ABSTRACT | FULL TEXT  

Myocardial Revascularization: Surgery or Stenting?
Wong et al.
Asian Cardiovasc. Thorac. Ann. 2007;15:264-269.
ABSTRACT | FULL TEXT  

Polymer-Based, Paclitaxel-Eluting TAXUS Liberte Stent in De Novo Lesions: The Pivotal TAXUS ATLAS Trial
Turco et al.
J Am Coll Cardiol 2007;49:1676-1683.
ABSTRACT | FULL TEXT  

A Cause for Concern
Camenzind et al.
Circulation 2007;115:1440-1455.
FULL TEXT  

Safety and Efficacy of Sirolimus- and Paclitaxel-Eluting Coronary Stents
Stone et al.
NEJM 2007;356:998-1008.
ABSTRACT | FULL TEXT  

Stent Thrombosis in Randomized Clinical Trials of Drug-Eluting Stents
Mauri et al.
NEJM 2007;356:1020-1029.
ABSTRACT | FULL TEXT  

Effectiveness of Drug-Eluting Stents in Patients With Bare-Metal In-Stent Restenosis: Meta-Analysis of Randomized Trials
Dibra et al.
J Am Coll Cardiol 2007;49:616-623.
ABSTRACT | FULL TEXT  

Development of Coronary Aneurysm after Drug-Eluting Stent Implantation
Bavry et al.
ANN INTERN MED 2007;146:230-232.
FULL TEXT  

The clinical outcome of percutaneous treatment of bifurcation lesions in multivessel coronary artery disease with the sirolimus-eluting stent: insights from the Arterial Revascularization Therapies Study part II (ARTS II)
Tsuchida et al.
Eur Heart J 2007;28:433-442.
ABSTRACT | FULL TEXT  

Pretreatment with intracoronary adenosine reduces the incidence of myonecrosis after non-urgent percutaneous coronary intervention: a prospective randomized study
Lee et al.
Eur Heart J 2007;28:19-25.
ABSTRACT | FULL TEXT  

Comparison of Zotarolimus-Eluting and Sirolimus-Eluting Stents in Patients With Native Coronary Artery Disease: A Randomized Controlled Trial
Kandzari et al.
J Am Coll Cardiol 2006;48:2440-2447.
ABSTRACT | FULL TEXT  

Mortality in randomized controlled trials comparing drug-eluting vs. bare metal stents in coronary artery disease: a meta-analysis
Nordmann et al.
Eur Heart J 2006;27:2784-2814.
ABSTRACT | FULL TEXT  

Treatment of In-Stent Restenosis -- Back to the Future?
Camenzind
NEJM 2006;355:2149-2151.
FULL TEXT  

Treatment of Coronary In-Stent Restenosis with a Paclitaxel-Coated Balloon Catheter
Scheller et al.
NEJM 2006;355:2113-2124.
ABSTRACT | FULL TEXT  

Vessel Size and Outcome After Coronary Drug-Eluting Stent Placement: Results From a Large Cohort of Patients Treated With Sirolimus- or Paclitaxel-Eluting Stents
Elezi et al.
J Am Coll Cardiol 2006;48:1304-1309.
ABSTRACT | FULL TEXT  

Intravascular Ultrasound in the Drug-Eluting Stent Era
Mintz and Weissman
J Am Coll Cardiol 2006;48:421-429.
ABSTRACT | FULL TEXT  

Cost Analysis From Two Randomized Trials of Sirolimus-Eluting Stents Versus Paclitaxel-Eluting Stents in High-Risk Patients With Coronary Artery Disease
Elezi et al.
J Am Coll Cardiol 2006;48:262-267.
ABSTRACT | FULL TEXT  

Periprocedural and Late Consequences of Overlapping Cypher Sirolimus-Eluting Stents: Pooled Analysis of Five Clinical Trials
Kereiakes et al.
J Am Coll Cardiol 2006;48:21-31.
ABSTRACT | FULL TEXT  

Narrative review: drug-eluting stents for the management of restenosis: a critical appraisal of the evidence.
Tung et al.
ANN INTERN MED 2006;144:913-919.
ABSTRACT | FULL TEXT  

Treatment of Stent Restenosis: Moving Beyond Momentum
Dauerman
J Am Coll Cardiol 2006;47:2161-2163.
FULL TEXT  

Predictive Factors of Restenosis After Coronary Implantation of Sirolimus- or Paclitaxel-Eluting Stents
Kastrati et al.
Circulation 2006;113:2293-2300.
ABSTRACT | FULL TEXT  

Drug eluting stents: an updated meta-analysis of randomised controlled trials
Roiron et al.
Heart 2006;92:641-649.
ABSTRACT | FULL TEXT  

The Year in Interventional Cardiology
Dixon et al.
J Am Coll Cardiol 2006;47:1689-1706.
FULL TEXT  

Paclitaxel-Eluting Stents vs Vascular Brachytherapy for In-Stent Restenosis Within Bare-Metal Stents: The TAXUS V ISR Randomized Trial
Stone et al.
JAMA 2006;295:1253-1263.
ABSTRACT | FULL TEXT